Research and Development Agreements (Tables) |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2022 | ||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Research and Development Revenues Disaggregated by Location |
Research and development revenue is attributable to regions based on the location of each of our collaboration partner's parent company headquarters. Research and development revenues disaggregated by location were as follows (in thousands):
|
|||||||||||||||||||||||||||||||||||||||||||||
| Millennium Pharmaceuticals Inc | ||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Research and Development Revenue from Related Party Relates to Revenue from Research and Development Agreements |
Research and development revenue from a previously related party was with Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (“Takeda”) and were as follows (in thousands):
|
|||||||||||||||||||||||||||||||||||||||||||||